Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 6/20 | 0.72 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.72 |
| ▸ | MEN1 | O00255 | 4/20 | 0.72 |
| ▸ | HTT | P42858 | 3/20 | 0.72 |
| ▸ | LMNA | P02545 | 3/20 | 0.72 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.72 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.61 |
| ▸ | RAB9A | P51151 | 1/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.59 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.57 |
| ▸ | MTOR | P42345 | 1/20 | 0.53 |
| ▸ | KDR | P35968 | 2/20 | 0.53 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.53 |
| ▸ | TP53 | P04637 | 2/20 | 0.53 |
| ▸ | POLB | P06746 | 1/20 | 0.53 |
| ▸ | KIF11 | P52732 | 1/20 | 0.52 |
| ▸ | CA12 | O43570 | 1/20 | 0.52 |
| ▸ | CA1 | P00915 | 1/20 | 0.52 |
| ▸ | CA2 | P00918 | 1/20 | 0.52 |
| ▸ | CA9 | Q16790 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22025453 | 0.86 | MAPT (0.70) | MAPTKMT2AMEN1HTTLMNA | |
| SCHEMBL31650490 | 0.86 | KMT2A (0.70) | MAPTKMT2AMEN1HTTLMNA | |
| SCHEMBL1455469 | 0.85 | MAPT (0.65) | MAPTKMT2AMEN1HTTLMNA | |
| SCHEMBL811365 | 0.85 | MAPT (0.60) | MAPTKMT2AMEN1HTTLMNA | |
| SCHEMBL17664539 | 0.85 | KMT2A (0.60) | MAPTKMT2AMEN1HTTLMNA | |
| SCHEMBL6813819 | 0.84 | LMNA (1.00) | MAPTKMT2AMEN1HTTLMNA | |
| SCHEMBL17103677 | 0.83 | TRPV1 (0.72) | MAPTKMT2AMEN1HTTLMNA | |
| SCHEMBL29572518 | 0.83 | TRPV1 (0.72) | MAPTKMT2AMEN1HTTLMNA | |
| SCHEMBL29591310 | 0.83 | MAPT (0.72) | MAPTKMT2AMEN1HTTLMNA | |
| SCHEMBL17103663 | 0.82 | MEN1 (0.75) | MAPTKMT2AMEN1HTTLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-4431959-B2 | — | — | 2010-03-17 | — | — | JP | claimed |
| US-20080221215-A1 | ANTIVIRAL INHIBITION OF CAPSID PROTEINS | SUMMERS MICHAEL F | 2008-09-11 | — | — | US | claimed |
| EP-1513959-A4 | ANTIVIRAL INHIBITIONS OF CAPSID PROTEINS | UNIV MARYLAND AT BALTIMORE COU (US) | 2008-07-23 | — | — | EP | claimed |
| JP-2005536717-A | — | — | 2005-12-02 | — | — | JP | claimed |
| EP-1513959-A2 | ANTIVIRAL INHIBITIONS OF CAPSID PROTEINS | University of Maryland at Baltimore County (US) | 2005-03-16 | — | — | EP | claimed |
| US-20030228573-A1 | Antiviral inhibition of capsid proteins | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2003-12-11 | — | — | US | claimed |
| WO-2003089615-A2 | ANTIVIRAL INHIBITIONS OF CAPSID PROTEINS | UNIVERSITY OF MARYLAND, BALTIMORE COUNTY (US) | 2003-10-30 | — | — | WO | claimed |
| US-20080221215-A1 | ANTIVIRAL INHIBITION OF CAPSID PROTEINS | SUMMERS MICHAEL F | 2008-09-11 | — | — | US | disclosed |
| EP-1513959-A4 | ANTIVIRAL INHIBITIONS OF CAPSID PROTEINS | UNIV MARYLAND AT BALTIMORE COU (US) | 2008-07-23 | — | — | EP | disclosed |
| US-7361459-B2 | Antiviral inhibition of capsid proteins | UNIVERSITY OF MARYLAND, BALTIMORE COUNTY (US) | 2008-04-22 | — | — | US | disclosed |
| US-7361459-B2 | Antiviral inhibition of capsid proteins | UNIVERSITY OF MARYLAND, BALTIMORE COUNTY (US) | 2008-04-22 | — | — | US | disclosed |
| EP-1815860-A2 | Phosphate transport inhibitors | GENZYME CORPORATION (US) | 2007-08-08 | — | — | EP | disclosed |
| US-20070021509-A1 | Phosphate transport inhibitors | JOZEFIAK THOMAS H | 2007-01-25 | — | — | US | disclosed |
| US-7119120-B2 | Phosphate transport inhibitors | GENZYME CORPORATION (US) | 2006-10-10 | — | — | US | disclosed |
| EP-1513959-A2 | ANTIVIRAL INHIBITIONS OF CAPSID PROTEINS | University of Maryland at Baltimore County (US) | 2005-03-16 | — | — | EP | disclosed |
| EP-1465638-A2 | PHOSPHATE TRANSPORT INHIBITORS | GENZYME CORPORATION (US) | 2004-10-13 | — | — | EP | disclosed |
| US-20040019113-A1 | Phosphate transport inhibitors | GELTEX PHARMACEUTICALS, INC. | 2004-01-29 | — | — | US | disclosed |
| US-20030228573-A1 | Antiviral inhibition of capsid proteins | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2003-12-11 | — | — | US | disclosed |
| WO-2003089615-A2 | ANTIVIRAL INHIBITIONS OF CAPSID PROTEINS | UNIVERSITY OF MARYLAND, BALTIMORE COUNTY (US) | 2003-10-30 | — | — | WO | disclosed |
| WO-2003057225-A2 | PHOSPHATE TRANSPORT INHIBITORS | GENZYME CORPORATION (US) | 2003-07-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040019113-A1 | Phosphate transport inhibitors | SLC34A1, SLC34A2, SLC20A1 | MAPT 3148/4885KMT2A 4536/4885MEN1 2905/4885 |
| US-20080221215-A1 | ANTIVIRAL INHIBITION OF CAPSID PROTEINS | CAPRIN1, CAPG, NCBP1 | MAPT 2146/4885KMT2A 4810/4885MEN1 4844/4885 |
| US-20030228573-A1 | Antiviral inhibition of capsid proteins | CAPRIN1, CAPG, NCBP1 | MAPT 2146/4885KMT2A 4810/4885MEN1 4844/4885 |
| US-20070021509-A1 | Phosphate transport inhibitors | SLC34A2, SLC34A1, SLC20A1 | MAPT 3058/4885KMT2A 4634/4885MEN1 2248/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.